MedPage Today (5/21, Susman) reports a systematic review and meta-analysis of three randomized trials presented at the American Psychiatric Association annual meeting found that “for people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting.” Researchers observed that “between 168 patients in the GLP-1 agonist groups and 169 control patients, the mean difference in post-cessation weight gain was -2.59 kg. However, the difference between groups in abstinence rates was not significantly different.” They noted that “experimental data suggest that GLP-1 receptor agonists, traditionally used for type 2 diabetes and obesity, may have a role in the pathophysiology of addiction, but its efficacy in nicotine abstinence remains unknown.” However, they could not “definitively say that using GLP-1s will help people stop smoking.”
Related Links:
— MedPage Today (requires login and subscription)